PDF下载 ( 1862 KB)
Toll样受体4与胰腺癌的关系
DOI: 10.3969/j.issn.1001-5256.2021.02.050
作者贡献声明：褚成龙负责课题设计，资料分析，撰写论文；唐朝辉、徐露瑶、李昌旭参与收集数据，修改论文；王英超负责拟定写作思路，指导撰写文章并最后定稿。
Association between Toll-like receptor 4 and pancreatic cancer
-
摘要: Toll样受体4(TLR4)是固有和适应性免疫反应的关键调节因子。TLR4在胰腺疾病方面的作用是近年的研究热点，已经有大量研究证明了TLR4与胰腺癌密切相关。主要探讨了TLR4在胰腺癌中的异常表达、调控机制，及其治疗癌症方面的潜力，以期为认识胰腺癌的发病机制和治疗提供新的启示。Abstract: Toll-like receptor 4 (TLR4) is a key regulator of innate and adaptive immune response. The role of TLR4 in pancreatic diseases is a research hotspot in recent years, and a large number of studies have shown that TLR4 is closely associated with pancreatic cancer. This article mainly discusses the abnormal expression and regulation mechanism of TLR4 in pancreatic cancer and its potential in cancer treatment, so as to provide new ideas for the pathogenesis and treatment of pancreatic cancer.
-
Key words:
- Pancreatic Neoplasms /
- Toll-Like Receptor 4 /
- Therapeutics
-
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492 [2] HUANG R, NI JJ, GAO Y. Relationship between intestinal flora-lipopolysaccharide- Toll-like receptor axis and hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34(6): 1325-1328. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.06.041黄蓉, 倪加加, 高毅. 肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系[J]. 临床肝胆病杂志, 2018, 34(6): 1325-1328. DOI: 10.3969/j.issn.1001-5256.2018.06.041 [3] PANARO MA, CORRADO A, BENAMEUR T, et al. The emerging role of curcumin in the modulation of TLR-4 signaling pathway: Focus on neuroprotective and anti-rheumatic properties[J]. Int J Mol Sci, 2020, 21(7): 2299. DOI: 10.3390/ijms21072299 [4] AWASTHI S. Toll-like receptor-4 modulation for cancer immunotherapy[J]. Front Immunol, 2014, 5: 328. http://www.ncbi.nlm.nih.gov/pubmed/25120541 [5] LU YC, YEH WC, OHASHI PS. LPS/TLR4 signal transduction pathway[J]. Cytokine, 2008, 42(2): 145-151. DOI: 10.1016/j.cyto.2008.01.006 [6] OCHI A, NGUYEN AH, BEDROSIAN AS, et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells[J]. J Exp Med, 2012, 209(9): 1671-1687. DOI: 10.1084/jem.20111706 [7] MAI CW, KANG YB, PICHIKA MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: Its expression and effects in the ten most common cancers[J]. Onco Targets Ther, 2013, 6: 1573-1587. http://www.ncbi.nlm.nih.gov/pubmed/24235843 [8] MAN XH, SUN YL, GONG YF, et al. Expression of toll-like receptor 4 in pancreatic cancer and its relationship with tumor angiogenesis[J]. Chin J Pancreatol, 2012, 12(3): 167-169. (in Chinese) DOI: 10.3760/cma.j.issn.1674-1935.2012.03.008满晓华, 孙运良, 龚燕芳, 等. Toll样受体4在胰腺癌组织中的表达及其与肿瘤血管生成的关系[J]. 中华胰腺病杂志, 2012, 12(3): 167-169. DOI: 10.3760/cma.j.issn.1674-1935.2012.03.008 [9] ZHANG JJ, WU HS, WANG L, et al. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma[J]. World J Gastroenterol, 2010, 16(23): 2881-2888. DOI: 10.3748/wjg.v16.i23.2881 [10] FAN P, ZHANG JJ, WANG B, et al. Hypoxia-inducible factor-1 up-regulates the expression of Toll-like receptor 4 in pancreatic cancer cells under hypoxic conditions[J]. Pancreatology, 2012, 12(2): 170-178. DOI: 10.1016/j.pan.2012.02.015 [11] ABREU MT, PEEK RM Jr. Gastrointestinal malignancy and the microbiome[J]. Gastroenterology, 2014, 146(6): 1534-1546.e3. DOI: 10.1053/j.gastro.2014.01.001 [12] PUSHALKAR S, HUNDEYIN M, DALEY D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J]. Cancer Discov, 2018, 8(4): 403-416. DOI: 10.1158/2159-8290.CD-17-1134 [13] MA X, WANG H, ZHANG P, et al. Association between small intestinal bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma and cholangiocarcinoma[J]. Turk J Gastroenterol, 2019, 30(2): 177-183. DOI: 10.5152/tjg.2018.17512 [14] BLOOMSTON M, ZERVOS EE, ROSEMURGY AS 2nd. Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials[J]. Ann Surg Oncol, 2002, 9(7): 668-674. DOI: 10.1007/BF02574483 [15] DEL POZO JL. Primers on molecular pathways: Lipopolysaccharide signaling-potential role in pancreatitis and pancreatic cancer[J]. Pancreatology, 2010, 10(2-3): 114-118. DOI: 10.1159/000299987 [16] IKEBE M, KITAURA Y, NAKAMURA M, et al. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway[J]. J Surg Oncol, 2009, 100(8): 725-731. DOI: 10.1002/jso.21392 [17] WU Y, LU J, ANTONY S, et al. Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-γ and lipopolysaccharide in human pancreatic cancer cell lines[J]. J Immunol, 2013, 190(4): 1859-1872. DOI: 10.4049/jimmunol.1201725 [18] XIE C, LIU D, CHEN Q, et al. Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-κB pathway[J]. Sci Rep, 2016, 6: 27528. DOI: 10.1038/srep27528 [19] ZHAO J, MENG Z, XIE C, et al. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma[J]. Int J Biochem Cell Biol, 2019, 108: 84-91. DOI: 10.1016/j.biocel.2019.01.011 [20] RUPAIMOOLE R, SLACK FJ. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3): 203-222. DOI: 10.1038/nrd.2016.246 [21] ZHOU M, CHEN J, ZHOU L, et al. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203[J]. Cell Immunol, 2014, 292(1-2): 65-69. DOI: 10.1016/j.cellimm.2014.09.004 [22] LIU J, XU D, WANG Q, et al. LPS induced miR-181a promotes pancreatic cancer cell migration via targeting PTEN and MAP2K4[J]. Dig Dis Sci, 2014, 59(7): 1452-1460. DOI: 10.1007/s10620-014-3049-y [23] BINKER-COSEN MJ, RICHARDS D, OLIVER B, et al. Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-κB/MMP-9 signaling pathway[J]. Biochem Biophys Res Commun, 2017, 484(1): 152-158. DOI: 10.1016/j.bbrc.2017.01.051 [24] LIU CY, XU JY, SHI XY, et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway[J]. Lab Invest, 2013, 93(7): 844-854. DOI: 10.1038/labinvest.2013.69 [25] WANG C, NING K, HU HH, et al. Research progress in tumor microenvironment of pancreatic cancer[J]. Chin J Dig Surg, 2020, 19(1): 109-112. (in Chinese) DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018王超, 宁克, 胡欢欢, 等. 胰腺癌肿瘤微环境的研究进展[J]. 中华消化外科杂志, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018 [26] DAS S, SHAPIRO B, VUCIC EA, et al. Tumor cell-derived IL1β promotes desmoplasia and immune suppression in pancreatic cancer[J]. Cancer Res, 2020, 80(5): 1088-1101. DOI: 10.1158/0008-5472.CAN-19-2080 [27] CHEN Q, WANG J, ZHANG Q, et al. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages[J]. Br J Cancer, 2019, 121(9): 786-795. DOI: 10.1038/s41416-019-0595-2 [28] GRIMMIG T, MOENCH R, KRECKEL J, et al. Toll like receptor 2, 4, and 9 signaling promotes autoregulative tumor cell growth and VEGF/PDGF expression in human pancreatic cancer[J]. Int J Mol Sci, 2016, 17(12): 2060. DOI: 10.3390/ijms17122060 [29] SUN Y, WU C, MA J, et al. Toll-like receptor 4 promotes angiogenesis in pancreatic cancer via PI3K/AKT signaling[J]. Exp Cell Res, 2016, 347(2): 274-282. DOI: 10.1016/j.yexcr.2016.07.009 [30] SUN YL, MA JX, MAN XH, et al. The role of p38 MAPK signaling pathway in the promotion of pancreatic cancer angiogenesis by TLR4[J]. Chongqing Med, 2017, 46(2): 161-164. (in Chinese) DOI: 10.3969/j.issn.1671-8348.2017.02.005孙运良, 马建霞, 满晓华, 等. p38 MAPK信号通路在TLR4促进胰腺癌血管生成中的作用[J]. 重庆医学, 2017, 46(2): 161-164. DOI: 10.3969/j.issn.1671-8348.2017.02.005 [31] ZHANG M, YAN L, WANG GJ, et al. Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4[J]. J Cell Physiol, 2019, 234(6): 9457-9466. DOI: 10.1002/jcp.27631 [32] CHEN X, CHENG F, LIU Y, et al. Toll-like receptor 2 and Toll-like receptor 4 exhibit distinct regulation of cancer cell stemness mediated by cell death-induced high-mobility group box 1[J]. EBioMedicine, 2019, 40: 135-150. DOI: 10.1016/j.ebiom.2018.12.016 [33] SHETAB BOUSHEHRI MA, LAMPRECHT A. TLR4-based immunotherapeutics in cancer: A review of the achievements and shortcomings[J]. Mol Pharm, 2018, 15(11): 4777-4800. DOI: 10.1021/acs.molpharmaceut.8b00691 [34] SHI XY, ZHAO J. Research progress of Gemcitabine in combined therapy of pancreatic cancer[J]. China Med Herald, 2020, 17(21): 50-53. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202021015.htm石雪英, 赵金. 吉西他滨在胰腺癌联合治疗方案中的研究进展[J]. 中国医药导报, 2020, 17(21): 50-53. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202021015.htm [35] MA JX, SUN YL, YU Y, et al. Triptolide enhances the sensitivity of pancreatic cancer PANC-1 cells to gemcitabine by inhibiting TLR4/NF-κB signaling[J]. Am J Transl Res, 2019, 11(6): 3750-3760. http://www.ncbi.nlm.nih.gov/pubmed/31312385 [36] ZHOU L, QI L, JIANG L, et al. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol[J]. AAPS J, 2014, 16(2): 246-257. DOI: 10.1208/s12248-013-9558-3 [37] XIE X, MA L, ZHOU Y, et al. Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo[J]. Carbohydr Polym, 2019, 225: 115223. DOI: 10.1016/j.carbpol.2019.115223 [38] ROSENDAHL AH, SUN C, WU D, et al. Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells[J]. Pancreatology, 2012, 12(6): 467-474. DOI: 10.1016/j.pan.2012.09.004 -
本文二维码
计量
- 文章访问数: 487
- HTML全文浏览量: 75
- PDF下载量: 25
- 被引次数: 0
下载:
